Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine

The CVnCoV (CureVac) mRNA vaccine for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was recently evaluated in a phase 2b/3 efficacy trial in humans(1). CV2CoV is a second-generation mRNA vaccine containing non-modified nucleosides but with optimized non-coding regions and enhanced ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Gebre, Makda S., Rauch, Susanne, Roth, Nicole, Yu, Jingyou, Chandrashekar, Abishek, Mercado, Noe B., He, Xuan, Liu, Jinyan, McMahan, Katherine, Martinot, Amanda, Martinez, David R., Giffin, Victoria, Hope, David, Patel, Shivani, Sellers, Daniel, Sanborn, Owen, Barrett, Julia, Liu, Xiaowen, Cole, Andrew C., Pessaint, Laurent, Valentin, Daniel, Flinchbaugh, Zack, Yalley-Ogunro, Jake, Muench, Jeanne, Brown, Renita, Cook, Anthony, Teow, Elyse, Andersen, Hanne, Lewis, Mark G., Boon, Adrianus C. M., Baric, Ralph S., Mueller, Stefan O., Petsch, Benjamin, Barouch, Dan H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770133/
https://www.ncbi.nlm.nih.gov/pubmed/34794169
http://dx.doi.org/10.1038/s41586-021-04231-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770133/
https://www.ncbi.nlm.nih.gov/pubmed/34794169
http://dx.doi.org/10.1038/s41586-021-04231-6

Ejemplares similares